1. Home
  2. IOVA vs LICN Comparison

IOVA vs LICN Comparison

Compare IOVA & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • LICN
  • Stock Information
  • Founded
  • IOVA 2007
  • LICN 2004
  • Country
  • IOVA United States
  • LICN China
  • Employees
  • IOVA N/A
  • LICN N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • LICN
  • Sector
  • IOVA Health Care
  • LICN
  • Exchange
  • IOVA Nasdaq
  • LICN Nasdaq
  • Market Cap
  • IOVA 771.4M
  • LICN 3.0M
  • IPO Year
  • IOVA N/A
  • LICN 2023
  • Fundamental
  • Price
  • IOVA $1.77
  • LICN $4.18
  • Analyst Decision
  • IOVA Buy
  • LICN
  • Analyst Count
  • IOVA 10
  • LICN 0
  • Target Price
  • IOVA $12.22
  • LICN N/A
  • AVG Volume (30 Days)
  • IOVA 11.7M
  • LICN 71.2K
  • Earning Date
  • IOVA 08-07-2025
  • LICN 01-01-0001
  • Dividend Yield
  • IOVA N/A
  • LICN N/A
  • EPS Growth
  • IOVA N/A
  • LICN N/A
  • EPS
  • IOVA N/A
  • LICN N/A
  • Revenue
  • IOVA $212,679,000.00
  • LICN $41,477,000.00
  • Revenue This Year
  • IOVA $86.62
  • LICN N/A
  • Revenue Next Year
  • IOVA $69.95
  • LICN N/A
  • P/E Ratio
  • IOVA N/A
  • LICN N/A
  • Revenue Growth
  • IOVA 11070.12
  • LICN 4.32
  • 52 Week Low
  • IOVA $1.64
  • LICN $2.60
  • 52 Week High
  • IOVA $12.51
  • LICN $488.00
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 39.26
  • LICN 46.64
  • Support Level
  • IOVA $1.67
  • LICN $4.00
  • Resistance Level
  • IOVA $1.82
  • LICN $4.41
  • Average True Range (ATR)
  • IOVA 0.11
  • LICN 0.25
  • MACD
  • IOVA -0.00
  • LICN 0.01
  • Stochastic Oscillator
  • IOVA 15.38
  • LICN 60.00

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

Share on Social Networks: